Do antimicrobial control programmes have a positive effect on patient outcomes?

Drugs and Therapy Perspectives

Volumn 20, Issue 9, 2004, Pages 22-26

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CLINICAL PATHWAY; CLINICAL STUDY; CLINICAL TRIAL; COST CONTROL; DATA ANALYSIS; DRUG CONTROL; DRUG EFFICACY; DRUG FORMULARY; DRUG USE; GRAM NEGATIVE INFECTION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MORTALITY; NONHUMAN; OUTCOMES RESEARCH; PATIENT CARE; PHARMACIST; PRACTICE GUIDELINE; SIDE EFFECT; TREATMENT PLANNING;

EID: 4544238045     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-200420090-00008     Document Type: Article

References (24)

1. Bearden DT, Allen GP. Impact of antimicrobial control programs on patient outcomes: pharmacy perspective. Dis Manage Health Outcomes 2003; 11 (11); 723-36
2. Wilton P, Smith R, Coast J, et al. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002; 7 (2): 111-7
3. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001; 29 (4 Suppl.): N114-20
4. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36 (1): 53-9
5. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997 Oct; 156 (4 Pt 1): 1040-8
6. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000; 162 (3 Pt 1): 837-43
7. Dominguez EA, Smith TL, Reed E, et al. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000; 21 (1 Suppl.): S4-8
8. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29 (6): 1101-8
9. Woodward RS, Medoff G, Smith MD, et al. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987; 83 (5): 817-23
10. Bamberger DM, Dahl SL. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch Intern Med 1992; 152 (3): 554-7
11. Gentry CA, Greenfield RA, Slater LN, et al. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm 2000; 57 (3): 268-74
12. White Jr AC, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25 (2): 230-9
13. Al-Eidan FA, McElnay JC, Scott MG, et al. Use of a treatment protocol in the management of community-acquired lower respiratory tract infection. J Antimicrob Chemother 2000; 45 (3): 387-94
14. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278 (1): 32-9
15. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283 (6): 749-55
16. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29 (6): 1109-15
17. Armstrong EP. Clinical and economic outcomes of an ambulatory urinary tract infection disease management program. Am J Manag Care 2001; 7 (3): 269-80
18. Pestotnik SL, Classen DC, Evans RS, et al. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124 (10): 884-90
19. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338 (4): 232-8
20. Fraser GL, Stogsdill P, Dickens Jr JD, et al. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med 1997; 157 (15): 1689-94
21. Lemmen SW, Becker G, Frank U, et al. Influence of an infectious disease consulting service on quality and costs of antibiotic prescriptions in a university hospital. Scand J Infect Dis 2001; 33 (3): 219-21
22. Gums JG, Yancey Jr RW, Hamilton CA, et al. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 1999; 19 (12): 1369-77
23. Barenfanger J, Short MA, Groesch AA. Improved antimicrobial interventions have benefits. J Clin Microbiol 2001; 39 (8): 2823-8
24. Cooke J. Antimicrobial management - the role of clinical pharmacists. Hosp Pharmacist 2003 Oct; 10 (9): 392-400